ZEN-3694

ZEN-3694 is an oral pan-BET (bromodomain and extra-terminal) inhibitor that Zenith Epigenetics originated and the National Cancer Institute now drives forward across at least five active combination trials [5][6][7][8][9]. The flagship Phase 2 program (NCT04471974) pairs it with enzalutamide and pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC), building on a 2020 Phase Ib/IIa study where the enzalutamide combination produced PSA50 responses (a 50% or greater drop in prostate-specific antigen, a blood marker of tumor burden) in patients who had already progressed on AR-targeted therapy [1][5]. ZEN-3694 has FDA Orphan Drug and Fast Track designations in NUT carcinoma - a real regulatory tailwind in that indication [11][12]. The bigger story: after Constellation's pelabresib delivered ambiguous Phase 3 data in myelofibrosis [10] and AbbVie shelved mivebresib, ZEN-3694 is one of the last oral pan-BET assets still pushing into solid tumors. For a target that genetics says should work and clinical reality keeps refusing to validate, this program is now where the BET class either earns a foothold or doesn't.

ZEN-3694 is a novel compound, not approved anywhere, with no marketed analog in its class. Zenith Epigenetics is a private Canadian biotech that has run the molecule through dose-finding and combination trials since the mid-2010s. The current development footprint is striking: most active trials list the NCI Cancer Therapy Evaluation Program as sponsor, with academic investigators at UCSF, Dana-Farber, and other centers running them under CTEP cooperative agreements [5][6][7][8][9]. That model gets science done cheaply but slows enrollment and dilutes the commercial narrative. Lead indication is mCRPC at Phase 2 (NCT04471974), with the ComBET trial of ZEN-3694 plus talazoparib in advanced solid tumors also at Phase 2 [5][6]. The TNBC (nab-paclitaxel + pembrolizumab) and NUT carcinoma combination programs (cisplatin/etoposide and abemaciclib arms) remain Phase 1 [7][8][9]. FDA has granted ZEN-3694 both Orphan Drug and Fast Track designations specifically in NUT carcinoma - the indication where BRD4 fusion biology gives the cleanest mechanistic rationale [11][12]. No breakthrough designation is on public record. There is no published registrational timeline. The first Phase Ib/IIa results came in 2020 [1]; six years later there is still no Phase 3 trial registered. That gap is itself a signal - Zenith has not pulled the trigger on a key program, likely because Phase 2 data has not been definitive enough to justify the spend or attract a partner. On the commercial side, Zenith announced an October 2023 collaboration with Cencora (formerly AmerisourceBergen) to support ZEN-3694 commercialization planning [13]; the last publicly disclosed equity financing for Zenith is the 2014 venture round (Crunchbase records ~$4.6M) [14], and the 2019 license to Newsoara covered only Greater China rights. The funding picture is opaque and old.

BET proteins (BRD2, BRD3, BRD4, and the testis-specific BRDT) are 'reader' proteins - they recognize acetylated histones, the chemical marks that tell the cell 'this stretch of DNA is open for transcription.' Think of them as bookmarks that recruit the rest of the transcription machinery to active genes. BRD4 is the one that matters most for cancer: it sustains transcription of MYC, BCL2, CDK6, and other genes that drive uncontrolled proliferation. Block BET reading and the tumor's growth program collapses. ZEN-3694 is an orally bioavailable small molecule that binds both bromodomains of the BET family and selectively inhibits BRD4 binding to super-enhancers, downregulating MYC and BCL2 family genes in preclinical models - the foundational pharmacology was reported by Attwell et al. at AACR 2016 [4]. In prostate cancer specifically, the rationale gets more interesting: BET inhibitors disrupt androgen receptor (AR) signaling at the chromatin level, and they also block a lineage switch where AR-driven prostate adenocarcinoma transdifferentiates into neuroendocrine prostate cancer, which is the resistance escape route after enzalutamide and abiraterone stop working [2]. Aggarwal's 2020 Phase Ib/IIa showed PSA50 responses in roughly a quarter of post-AR-therapy mCRPC patients, with PSA declines correlating with BET-target gene downregulation in tumor biopsies [1]. How strong is the case? Genetics say BRD4 is a real cancer dependency, MYC suppression alone would be a generational win if achievable, and knockdown studies reproduce the effect in models. But every pan-BET inhibitor tested in humans has run into the same wall: the same transcription program you want to shut down in tumor cells is also load-bearing in normal megakaryocytes (platelet-producing cells in the bone marrow) and gut epithelium.

The lead readout is NCT04471974: a Phase 2, single-arm, investigator-initiated study of ZEN-3694 plus enzalutamide plus pembrolizumab in mCRPC patients who have progressed on prior AR-targeted therapy [5]. Trial design per the UCSF registration: a 6-patient safety lead-in followed by expansion cohorts, target total enrollment approximately 61, with ZEN-3694 and enzalutamide dosed orally once daily on days 1-21 and pembrolizumab 200 mg IV on day 1 of a 21-day cycle. The primary endpoint is composite response rate (PSA50 plus RECIST-defined objective response in measurable disease). The trial is run out of UCSF with Rahul Aggarwal as principal investigator; per the public registration the study is in progress but not currently accepting new patients, with estimated completion in May 2028. Without a comparator arm, the readout has to be benchmarked against historical controls, which is a structural limitation when the biggest question is whether adding ZEN-3694 to standard enzalutamide actually moves overall survival or just shifts surrogate biomarkers. The broader trial portfolio is more interesting than the prostate study alone. ComBET (NCT05327010) is a Phase 2 of ZEN-3694 plus talazoparib (a PARP inhibitor) across advanced solid tumors with ORR as primary endpoint and an enrollment target of 88 [6]. The TNBC program (NCT05422794) tests ZEN-3694 with pembrolizumab and nab-paclitaxel, n=57 [7]. NUT carcinoma is a rare, aggressive cancer driven by BRD4 fusion genes; it has a Phase 1/2 with cisplatin and etoposide chemotherapy (NCT05019716, target n=55, ~18 enrolled as of recent updates) and a Phase 1 with abemaciclib (NCT05372640, n=45) [8][9]. NUT carcinoma is the cleanest biological match for a BET inhibitor since the disease is literally defined by a BRD4 oncogenic fusion. If ZEN-3694 cannot show responses in NUT carcinoma, the broader solid-tumor strategy is in trouble.

Our model gives this drug an 8% chance of eventually reaching approval. That starts from a historical benchmark of about 13% for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and its sponsor. The estimate is nudged upward by a non-randomized design and open-label blinding, but pulled down by the sponsor's thin approval record and weak earlier-phase results. The remaining factors were typical for this stage and left the number close to where it started.

The efficacy risk is class-defining: pan-BET inhibition shuts down dozens of transcription programs simultaneously, and the therapeutic window between 'kills tumor' and 'kills the patient's bone marrow' has been the central problem of the entire field. Aggarwal's 2020 paper reported PSA50 responses in roughly 24% of mCRPC patients, which is workmanlike but not the dramatic signal that justifies a Phase 3 spend [1]. In the current mCRPC trial, the triplet with enzalutamide and pembrolizumab introduces a confound: is any response coming from ZEN-3694, or from the subset of MSI-high (microsatellite-instability-high - tumors with a DNA mismatch-repair defect that makes them respond better to checkpoint inhibitors) or otherwise immunogenic patients who would have responded to pembrolizumab alone? Safety risk is mechanism-based and well-cataloged. Thrombocytopenia is the limiting toxicity for every pan-BET inhibitor because BRD4 is required for megakaryocyte (platelet-producing bone marrow cell) differentiation, so blocking it drops platelets. GI toxicity, fatigue, and dysgeusia (taste loss) are also class effects [1]. None of these are dose-finding mysteries; they are predictable problems that constrain combinations. Execution risk is real. Zenith Epigenetics is a private company with limited disclosed capital - the last public equity round on record is 2014 [14] - and the 2023 Cencora collaboration covers commercialization support, not a major upfront cash infusion [13]. Running most trials through NCI/CTEP is scientifically responsible and financially efficient, but it does not produce industrial-scale enrollment or commercial-grade timeline discipline. A Phase 3 would require a partner, an IPO, or a licensing deal beyond the existing Newsoara China rights, none publicly announced for global territories. Commercial risk: even with positive mCRPC data, the combination would compete against enzalutamide plus chemotherapy and PARP-inhibitor backbones in a U.S. mCRPC population of roughly 40,000-50,000 men annually, and payers will demand overall survival benefit, not PSA changes alone.

Worth watching, but watch the right readout. The mCRPC Phase 2 (NCT04471974) is the lead asset, but the cleaner biological signal will come from the NUT carcinoma trials (NCT05019716, NCT05372640), where BRD4 is the actual oncogenic driver via gene fusion and where ZEN-3694 already holds Orphan Drug and Fast Track designations [8][9][11][12]. If ZEN-3694 cannot deliver responses in NUT carcinoma, the broader solid-tumor pitch is hollow. The specific data point that would convert this from background to signal: a PSA50 response rate above ~35% in the triplet combination - meaningfully higher than the ~24% PSA50 from the Phase Ib/IIa monotherapy-plus-enzalutamide combination, enough margin to justify Phase 3 investment - or any confirmed objective response in NUT carcinoma at the recommended Phase 2 dose. Watch for NCI cooperative-group data updates and any peer-reviewed publication from the ComBET trial; no specific ASCO/ESMO 2026 abstracts have been disclosed publicly at writeup time. The structural question for Zenith Epigenetics is whether they can find a global partner before cash runs short. With the last disclosed equity round in 2014 and the only large recent commercial deal being the 2023 Cencora commercialization collaboration [13][14], a partnership or financing announcement - more than any single trial readout - is what will decide whether ZEN-3694 ever reaches a registrational study.